Asthma is a complex inflammatory condition often associated with bronchial hyperreactivity and atopy. Genetic and environmental factors are implicated and several candidate genes have been implicated. Of these, the chemokine RANTES is responsible for the recruitment of inflammatory cells such as eosinophils and T-lymphocytes. We have recently identified a polymorphism within the RANTES promoter (−403 G →A) and have examined its role, using a PCR-RFLP assay, in the development of atopy and asthma in 201 Caucasian subjects. Atopic status was determined using skin prick testing and serum IgE levels. Severity of airway dysfunction was assessed using spirometric measurement (FEV 1 ) and methacholine challenge (PC 20 ). The −403 A allele was associated with an increased susceptibility to both atopy and asthma. Thus, the proportion of subjects carrying this allele was higher in each of atopic non-asthmatics, nonatopic asthmatics and atopic asthmatics compared with non-atopic, non-asthmatic controls. In particular, this allele was associated with skin test positivity but not IgE level. Homozygosity for the −403 A allele conferred a 6.5-fold increased risk of moderate/severe airway obstruction (FEV 1 р80% predicted), a marker for established asthma. Our data, whilst preliminary, indicate that the association of RANTES genotype with both atopy and asthma reflect independent effects, suggesting different mechanisms for the role of this chemokine in atopy and development of airway obstruction. Genes and Immunity (2000) 1, 509-514.
Introduction
Future therapeutic strategies in asthma are likely to be influenced by our increased understanding of the genetic factors involved in its aetiopathogenesis. While asthma is oligogenic, present knowledge suggests that candidate genes include those that determine its two key clinical phenotypes; bronchial hyperresponsiveness (BHR) and atopy. BHR, an exaggerated response to bronchoconstrictors, is a critical clinical phenotype demonstrated by virtually all patients with asthma. BHR reflects the presence of bronchial inflammation and in general, its severity parallels that of asthma symptoms. 1 Atopy, though an important component of asthma, is not alone sufficient to cause the disease; whilst 30-50% of the population are atopic, only 5-7% will develop asthma. 2 Furthermore, since individuals who are atopic are significantly more likely to have increased airway responsiveness, 2 assessment of genetic risk must consider the possible interaction of these two components in the expression of the asthma phenotype. The immune response underlying the development of asthma has attracted considerable interest since many immune mediators have been shown to play a role in mediating the bronchial airway inflammation that accompanies allergic asthma. In particular, the genes encoding cytokines involved in the Th1-Th2 switch seen in asthmatics have been intensively studied. These include the interleukin-4 cytokine cluster on chromosome 5q31-33 (eg, IL-4, IL-5 and IL-13), and interferon-␥ on chromosome 12q. [3] [4] [5] A strong argument can be made for the chemokine RANTES as a candidate gene in asthma. This mediator has the ability to attract several types of inflammatory cells including monocytes, eosinophils and memory Thelper (Th) cells to the site of inflammation. 6, 7 Furthermore, increased levels of RANTES and other members of the C-C family of chemokines (MIP-1␣, MCP-1) have been detected in the nasal secretions of atopic patients exposed to local allergen challenge 8 and were found in higher levels in the bronchial lavage fluid of patients with active asthma. 9 RANTES has also been found at significantly higher levels in patients during asthma attacks than in those with asymptomatic stages or in controls. 10 In addition, the number of eosinophils recruited to the lung is strongly correlated with the concentration of immunoreactive RANTES. 11 We 12 and others 13 have recently described a single nucleotide polymorphism (G→A at position −403) in the promoter region of the RANTES gene. The less common −403 A allele was associated with atopic dermatitis in German children but not with asthma. 13 Transient transfections of human mast cell line and T cell line with reporter vector controlled by the wild or mutant allele of RANTES promoter (−403 G/A) showed an 8-fold increased constitutive transcription activity of the mutant allele. 13 In the current study, we have examined the hypothesis that this polymorphism is associated with asthma and the related phenotypes, atopy and physiological airway dysfunction. We have determined, for the first time, the frequency of RANTES genotypes in a population of subjects stratified by atopic status (serum IgE level and skin prick tests), as well as degree of obstruction (airway calibre) and BHR.
Results
The characteristics of the recruited subjects are summarised in Table 1 . Table 2 shows the RANTES genotype and allele frequencies in non-atopic non-asthmatics, atopic non-asth- matics, non-atopic asthmatics and atopic asthmatics. Compared with non-atopic non-asthmatic subjects, the frequency of individuals homo-or heterozygous for the −403 A allele (AG and AA genotypes combined) was significantly increased in atopic asthmatic (P = 0.019) and atopic non-asthmatic (P = 0.003) subgroups ( Figure 1) . A similar trend was seen for the non-atopic asthmatics subgroup though this just failed to achieve statistical significance (P = 0.072). Similar significant associations were obtained when allele frequencies were compared in the four groups (Table 2) . Odds ratios for the risk associated with homo-and heterozygosity for the A allele in subjects from the North Staffordshire and Wythenshawe populations were, when examined separately, similar in atopic asthmatic (2.7 and 3.3, respectively) and atopic non-asthmatic (5.7 and 3.3, respectively) subjects. Table 3 shows RANTES genotype and allele frequencies in relation to the atopic indices; skin test positivity and serum IgE level. No significant associations were identified between RANTES genotype and IgE level, though the frequency of the genotypes carrying the −403 A allele were significantly increased in individuals with a positive skin prick test (P = 0.028) compared with skin test negative individuals. When allele frequencies were examined, the A allele was also more common in those with a positive skin prick test compared with skin prick test negative individuals, though this just failed to achieve statistical significance (P = 0.054, OR = 1.7, 95% CI = 1.0-3.0). When excluding non-atopic asthmatic patients, the association with the −403A genotypes remained significant (OR = 2.9, 95% CI = 1.4-6.1, P = 0.005). Again, a similar trend was identified in both North Staffordshire and Wythenshawe subjects, when analysed separately, though significance (P = 0.049) was only achieved in the Wythenshawe cohort.
Association of RANTES genotype with the clinical subgroups

Association of RANTES genotype with atopic indices
Association of RANTES genotypes with severity of airway obstruction/reactivity
Lung function tests (FEV 1 and methacholine challenge) were available on the North Staffordshire cohort. The association of RANTES genotype with degree of airway obstruction (FEV 1 ) was analysed using two approaches. Firstly, since an FEV 1 of Ͻ80% predicted is considered a marker of moderate/severe airway dysfunction, genotype and allele frequencies in patients with an FEV 1 Figure 1 RANTES genotype frequencies in non-atopic non-asthmatic, atopic non-asthmatic, non-atopic asthmatic and atopic asthmatic subjects. Ͻ80% predicted were compared with those with an FEV 1 у80% predicted (dichotomous outcome) using logistic regression (Table 4) . Secondly, as a confirmatory analysis, genotype associations were examined with FEV 1 expressed as a continuous variable using linear regression. Using the dichotomous outcome, the −403 A carrying genotypes demonstrated a gene dosage effect, with moderate/severe airway obstruction (р80% percentage predicted) being associated with higher fre- AG vs GG genotype; P = 0.241, OR = 1.5, 95% CI = 0.7-3.2. AA vs GG genotype; P = 0.031, OR = 6.5, 95% CI = 1.2-35. A vs G allele; P = 0.024, OR = 1.9, 95% CI = 1.1-3.3.
Genes and Immunity quency of both the AG and AA genotypes. Though the increase in the AG genotype did not achieve significance, the AA genotype was associated with a 6.5-fold increased risk of moderate/severe airway obstruction (P = 0.031) compared with GG. Significant results were also obtained when allele frequencies were considered ( Examination of associations between RANTES genotypes and degree of BHR according to the stratification described in the Materials and methods section (groups 1-4) identified no significant effects.
Discussion
We describe, for the first time, an association between polymorphism within the RANTES gene promoter and risk of asthma and atopy. In this preliminary analysis, the −403 A allele was found to be associated with increased risk of atopy defined as a positive skin prick test to aeroallergen, but not serum IgE levels. Furthermore, homozygosity for this allele was found to be associated with increasing severity of airway obstruction. In particular, subjects with the AA genotype demonstrated a 6.5-fold increased risk of moderate/severe airway obstruction compared with those with the GG genotype. These associations were identified in each of atopic nonasthmatic, non-atopic asthmatic and atopic asthmatic subjects, suggesting that the associations with asthma and atopy operate through independent mechanisms. This view is supported by our data showing that correction for skin test positivity did not abolish the association between RANTES genotype and airway obstruction. However, numbers of individuals in some groups were small and therefore these data should be confirmed in larger patient cohorts.
In our analyses, we have examined both genotype and allele frequencies. In some cases, the frequency of the AA genotype was not sufficiently common to allow accurate statistical analysis of this genotype alone and we have therefore considered AA and AG genotypes combined. Since studies on the functional consequence of this polymorphism have shown that the A allele, which results in the abolishment of a GATA transcription factor motif, is associated with an eight-fold higher constitutive transcriptional activity. 13 It is reasonable to consider genotypes containing this allele (AA and AG genotypes) as high producers, though the possibility of a gene dosage effect at this locus remains unclear.
In a study by Liu et al, 14 the −403 polymorphism was found to form three haplotypes with a further single nucleotide substitution at position −28 (G→C), one of which (−403A/−28G) encodes higher RANTES production in vitro. Since −403*A is in strong linkage disequilibrium with the −28 G allele, we would predict that the −403 A allele is also associated with increased production. This view has subsequently been confirmed by Nickel et al. 13 Furthermore, we have recently shown that the −403 A allele is associated with increased susceptibility to polymyalgia rheumatica and rheumatoid arthritis 15 and with delayed progression of HIV infection. 16 Together with a complex network of other cytokines and chemokines, RANTES is a critical mediator in the airway inflammatory process that characterizes asthma. Indeed, linkage and molecular epidemiology studies have shown that several other such mediators (IL-4, IL-5, IL-13, interferon-␥) are candidates for susceptibility to asthma. [3] [4] [5] RANTES is produced by T-lymphocytes and monocytes and acts as a chemoattractant for several cell types (eg, mast cells, basophils, T-lymphocytes, eosinophils) 6, 7 which are central to the inflammatory cascade. Therefore, increased production of RANTES would be predicted to result in enhanced recruitment of proinflammatory cells to the target site, precipitating an amplified local inflammatory reaction. This is consistent with data showing that its expression is upregulated in several inflammatory conditions, such as rheumatoid arthritis 17 and multiple sclerosis, 18 as well as asthma. [8] [9] [10] [11] Our data indicated that −403 A is more common in asthmatics, both atopic and non-atopic. This observation is supported by Ying et al 19 who showed that RANTES expression was higher in bronchial mucosa from both types of asthma. On the other hand, Nickel et al 13 found no association between this polymorphism and asthma in children. Whether this reflects differences in the genetic susceptibility to asthma in adults vs children needs to be investigated further.
Exposure to allergen during skin prick testing results in recruitment of memory T-lymphocytes as well as basophils and mast cells to the challenge site. In atopic subjects, recognition of allergen by the recruited memory Tcells results in release of factors such as histamine, platelet activating factor and prostaglandin D2 from basophils and mast cells giving rise to the immediate local cutaneous reaction. RANTES is critical to memory T-cell recruitment 6 and can provoke release of histamine and prostaglandin D2 from intradermal basophils and mast cells, [20] [21] [22] suggesting that this chemokine is involved in the inflammatory response that characterizes immediate hypersensitivity reactions. However, RANTES is not known to directly influence IgE class switch or circulating levels. 23 It is interesting to speculate, therefore, that this may explain our findings of an association of the −403 A allele with skin test positivity but not IgE levels. Furthermore, the importance of the RANTES −403 A allele in mediating cutaneous response to allergen challenge has recently been demonstrated in studies showing that this allele is associated with an increased risk of atopic dermatitis in children. 13 RANTES can mediate its function through binding to several receptors, including CCR1, CCR3, CCR4 and CCR5. 24 Recent data shows that CCR3 expression is significantly higher in the bronchial mucosa of atopic asthmatics than normal controls. 25 Further, Hall et al 26 recently demonstrated a decreased risk for the development of childhood asthma in the presence of the CCR5 ⌬32 mutation. We have now shown, for the first time, an association between the −403 RANTES polymorphism and increasing severity of airway obstruction (as measured by FEV 1 ), but not with BHR (as measured by methacholine challenge testing). BHR acts via a similar mechanism to the immediate hypersensitivity reaction seen in cutaneous exposure to allergen. However, since the use of agents such as methacholine and histamine used in challenge tests for BHR do not require recruitment of memory T-cells or release of mediators from the local cell population, the role of RANTES is bypassed. RANTES would be predicted, however, to be more important in mediating bronchial hyperresponsiveness to an inhaled allergen to which the individual is sensitive, since this more accurately reflects the cutaneous immediate reaction. In the context of the development of the persistent inflammation that underlies asthma-related physiological dysfunction, we postulate that, since the eosinophils recruited by RANTES 11 are a major source of the reactive oxygen species released during the inflammatory process, chronically elevated levels of the chemokine (with other released C-C chemokines) may at least in part result in significant damage to the airway wall necessitating airway remodeling. This would be reflected in a reduction of airway caliber and consequently, a lowering of the percentage predicted FEV 1 . This view is supported by data showing that production of profibrotic cytokines such as TGF␤1 by eosinophils correlates with airway thickening and a reduction in FEV 1 . 27 Thus, RANTES may be important in determining the severity of the persistent inflammation leading to airway remodeling and bronchial response to inhaled aeroallergen.
These preliminary findings if confirmed in a larger independent cohort, may be exploited clinically as RANTES antagonists could be of considerable therapeutic efficacy in modifying the underlying inflammation present in these patients. Perhaps such an approach would be of particular benefit in those patients who are genetically predisposed to high levels of RANTES production (ie, those with the −403 A allele).
Materials and methods
Subject recruitment
A total of 201 unrelated Northern European Caucasians were recruited from subjects attending the Department of Respiratory Medicine, North Staffordshire Hospital (n = 155) and Lung Function Unit, Wythenshawe Hospital, Manchester (n = 46). These hospitals are less than 40 miles apart and serve neighbouring populations. The study protocol was approved by the local Ethics Committees and all subjects provided written informed consent. Positivity to the skin prick test (wheal diameter у3 mm greater than saline control) to a panel of seven common aeroallergens (house dust mite, house dust, grass mix, tree pollen, cat fur, dog fur, feathers) and/or total serum IgE levels у100 IU/ml were used to define atopic status in all recruited subjects. Spirometric measurements, including forced expiratory volume in 1 second (FEV 1 ), forced vital capacity (FVC) and peak expiratory flow (PEF) were performed in all subjects according to the British Thoracic Society recommendations. Bronchial responsiveness was assessed by measuring the provocative concentration of methacholine causing a 20% fall in FEV 1 (PC 20 ) . A wash-out period of short-acting inhaled bronchodilators (12 h) and anti-histamines (1 week) was observed before the assessment visit. All patients were lifelong non-smokers and none had suffered an exacerbation or respiratory infection within the previous 6 weeks.
Non-atopic, non-asthmatic subjects were defined by normal lung function, a serum IgE of ͘100 IU/ml and a negative skin prick test to aeroallergen. Atopic non-asthmatic subjects were defined by a personal history of allergy, seasonal rhinitis, eczema or allergic conjunctivitis in addition to positive skin prick tests and/or total serum IgE level Ͼ100 IU/ml in the absence of physiological airway obstruction. Subjects were diagnosed as asthmatic by a history of wheezing, cough, dyspnoea and/or chest tightness, and spirometric demonstration of airflow obstruction reversible with a ␤ 2 -agonist bronchodilator (Ͼ15% change in FEV 1 ).
Methacholine challenge testing
Methacholine challenge test data were available only on subjects recruited from the from North Staffordshire hospital. Ethical constraints prevented methacholine challenge testing on individuals exhibiting a FEV 1 р80% of the predicted value. Aerosols of methacholine were generated by a jet nebuliser according to the Dosimeter method as described previously. 28 
Subject stratification
According to the degree of airway dysfunction, subjects were stratified into four groups: Group 1; FEV 1 Ͼ80% predicted and PC 20 Ͼ16 mg/ml (BHR-negative), Group 2; FEV 1 Ͼ80% predicted and PC 20 positive with a dose of methacholine of 8-16 mg/ml (borderline BHR), Group 3; FEV 1 Ͼ80% predicted and PC 20 positive with a dose of methacholine of 0.03-8 mg/ml (BHR-positive), Group 4; FEV 1 р80% predicted (moderate/severe airway dysfunction) ( Table 1) . Subjects who have an FEV 1 р80% predicted are likely to demonstrate hyperresponsiveness, but are less likely to be able to perform the test. Accordingly, methacholine challenge tests were not performed on patients in Group 4.
Identification of RANTES genotypes
Leukocyte DNA was extracted from peripheral blood (5 ml) collected into EDTA using standard phenol/ chloroform procedures. The RANTES gene promoter single nucleotide polymorphism (G→A transition at position −403) was identified according to the method of Hajeer et al. 12 Since neither the wild-type nor the mutant allele abolishes or introduces a restriction enzyme site, a single base change was introduced in the forward primer at position −396 (C→G), thus creating an enzyme site that can be used to differentiate between wild-type and mutant alleles. Forward 5Ј-GCCTCAATTTACAG TGTG-3Ј and reverse 5Ј-TGCTTATTCATTACAGATGTT-3Ј primers were used to amplify genomic DNA. PCR reactions were carried out in a 25 l final volume, containing 1 × NH 4 buffer (Bioline), 1.5 mm MgCl 2 , 0.2 mm dNTPs (Bioline), 6.3 pmol of each primer, 1U Taq polymerase (Bioline) and 1 mm Betaine (Sigma). PCR cycles were as follows: 95°C for 2 min followed by 35 cycles each of 95°C for 40 sec, 50°C for 40 sec and 72°C for 40 sec. A final extension step was carried out at 72°C for 5 min. In the presence of the wild-type allele, the Mae III enzyme cuts the PCR product giving two bands of 112 and 23 bp, while in the presence of the mutant allele the PCR product remains refractory to digestion. Fragments were visualised on 3% agarose gel stained with ethidium bromide.
Statistical analysis
Chi-squared tests were used to assess homogeneity between groups (eg, skin test positive vs skin test negative). As some allele frequencies were small, the StatXact-Turbo (version 3, Cytel Software Corporation, Cambridge, MA, USA) statistical package was used where appropriate. All other statistical analyses were performed using the Stata statistical package (version 6, Stata Corporation, College Station, TX, USA). To correct for imbalances in skin test positivity between groups, logistic regression was used. Assessment of associations between RANTES genotype and airway obstruction (FEV 1 ) was analysed using two approaches: comparison of genotype frequency in patients with an FEV 1 Ͻ80% predicted with that in those with FEV 1 у80% predicted (dichotomous outcome) using logistic regression, and examining genotype associations with FEV 1 expressed as a continuous variable using linear regression.
